Analyst Price Targets — TVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 25, 2026 11:38 am | Vamil Divan | Guggenheim | $65.00 | $59.40 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim |
| June 2, 2026 3:38 pm | Joseph Pantginis | H.C. Wainwright | $67.00 | $42.96 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright |
| April 14, 2026 3:15 pm | — | Piper Sandler | $49.00 | $41.11 | TheFly | Travere Therapeutics upgraded to Overweight from Neutral at Piper Sandler |
| April 14, 2026 11:34 am | — | Guggenheim | $54.00 | $30.70 | TheFly | Travere Therapeutics price target raised to $54 from $49 at Guggenheim |
| January 14, 2026 11:48 am | Vamil Divan | Guggenheim | $49.00 | $28.39 | StreetInsider | Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX) |
| September 10, 2025 2:48 pm | Maury Raycroft | Jefferies | $35.00 | $27.31 | TheFly | AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies |
| October 31, 2024 8:21 pm | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI |
| October 21, 2024 5:38 am | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | StreetInsider | Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight |
| October 10, 2024 9:24 am | Liisa Bayko | Evercore ISI | $30.00 | $18.07 | TheFly | Travere Therapeutics price target raised to $30 from $12 at Evercore ISI |
| October 9, 2024 6:57 am | Jason Zemansky | Bank of America Securities | $20.00 | $15.21 | TheFly | Travere Therapeutics price target raised to $20 from $18 at BofA |
Latest News for TVTX
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or…
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVTX.
U.S. House Trading
No House trades found for TVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.